Control Bionics Limited (ASX:CBL)

Market Cap	28.24M +139.9%
Revenue (ttm)	4.77M -22.4%
Net Income	-7.27M
EPS	-0.02
Shares Out	543.09M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	252,176
Open	0.0530
Previous Close	0.0530
Day's Range	0.0520 - 0.0530
52-Week Range	0.0320 - 0.0950
Beta	0.06
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 24, 2026

About Control Bionics

Control Bionics Limited, together with its subsidiaries, engages in the research, development, commercialization, and sale of assistive communications technology systems in Australia, North America, Japan, and internationally. It offers NeuroNode Trilogy, NeuroNode Duo, and Eye-gaze Duo systems that allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. The company also provides the NeuroStrip, a wearable, miniaturized elect...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2005
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: CBL

Financial Performance

In fiscal year 2026, Control Bionics's revenue was 4.77 million, a decrease of -22.43% compared to the previous year's 6.14 million. Losses were -7.27 million, 18.9% more than in 2025.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 28, 2026

Data Sources Report a data error